Vor bio provides clinical update further validating approach of using shielded transplants to deliver targeted therapies; receives supportive feedback from fda regarding registrational trial design

Cambridge, mass., dec. 09, 2024 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing phase 1/2 vbp101 study of patients with relapsed/refractory aml receiving trem-cel followed by mylotarg™. the data, which was presented in a poster at the american society of hematology (ash) annual meeting on sunday, december 8th, demonstrated durable engraftment, shielding from mylotarg on-target toxicity, a broadened mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk aml comparators.
VOR Ratings Summary
VOR Quant Ranking